Cannabinoid Encyclopedia

Cannabinoid guide

What is CBGA?

A clear guide to CBGA: what it is, what researchers have studied, how strong the evidence is, and what to know about safety.

Updated July 2026 33 research sources Human and early research

The short answer

CBGA, in simple terms

CBGA is a cannabinoid-related compound represented in the scientific literature. Researchers study it for possible effects, safety, and how it works in the body. The source set includes human research as well as earlier-stage studies. The evidence does not turn this into one proven benefit, because studies can use different products, doses, routes, people, and outcomes. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about CBGA.

Why people look into itSee the main questions before the research details. What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Why people look into CBGA

What CBGA is commonly talked about for

These cards show the questions most represented in this source set. They are not a list of proven benefits, and the evidence label matters as much as the topic name.

  1. Mostly mechanism-focused

    Receptors and pharmacology

    This is part of the biological explanation for why CBGA may have effects in cells or models. Mechanism research does not by itself show a health benefit in people. 2

    See research areas

  2. Human and early-stage research

    Skin and inflammatory dermatology

    Skin interest comes from cell, topical, or model-system research involving CBGA. That early work does not establish a benefit for a skin condition in people. 3

    See research areas

  3. Human and early-stage research

    Appetite and metabolic outcomes

    Researchers have looked at CBGA in appetite or metabolism-related models. That does not show that it changes appetite, weight, or metabolism for people. 4

    See research areas

  4. Mostly mechanism-focused

    Nausea-related or inflammation-related outcomes

    Interest in CBGA and inflammation comes from studies of inflammatory or immune signals. A change in a laboratory or animal model is not proof of a human treatment effect. 5

    See research areas

Bottom line: Start with the exact question you care about, then check the study type, product, dose, and outcome before treating a research signal as a real-world effect.

Key takeaways

What to know first

  1. 1

    Research on CBGA covers Receptors and pharmacology, Skin and inflammatory dermatology, and Appetite and metabolic outcomes; those areas should not be combined into one claim. 1

  2. 2

    The source set includes human research as well as earlier-stage studies. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What has CBGA been studied for?

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Mostly mechanism-focused

Receptors and pharmacology

Researchers have examined CBGA in connection with Receptors and pharmacology. The studies may differ in compound, formulation, dose, route, population, and outcome. 2

Human and early-stage research

Skin and inflammatory dermatology

Researchers have examined CBGA in connection with Skin and inflammatory dermatology. The studies may differ in compound, formulation, dose, route, population, and outcome. 3

Human and early-stage research

Appetite and metabolic outcomes

Researchers have examined CBGA in connection with Appetite and metabolic outcomes. The studies may differ in compound, formulation, dose, route, population, and outcome. 4

Mostly mechanism-focused

Nausea-related or inflammation-related outcomes

Researchers have examined CBGA in connection with Nausea-related or inflammation-related outcomes. The studies may differ in compound, formulation, dose, route, population, and outcome. 5

Too limited for a firm answer

Pain-related outcomes

Researchers have examined CBGA in connection with Pain-related outcomes. The studies may differ in compound, formulation, dose, route, population, and outcome. 6

Mostly mechanism-focused

Receptor, target, metabolic, and pharmacology mechanisms

Studies connect CBGA with Receptor, target, metabolic, and pharmacology mechanisms at the level of receptors, enzymes, signaling, or pharmacology. This helps explain how the biology might work, but it does not prove a health outcome. 7

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

9 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

6 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

11 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

Another 7 of 33 research sources could not be placed cleanly into those three groups from the recorded study details.

What these studies actually looked at

The research on CBGA is not one kind of study. This source set includes 6 narrative or expert reviews, 5 animal studies, 5 cell or laboratory studies, and 3 clinical studies in people. 3

The recorded populations or models include people or patients (10 sources), animal models (3 sources), and cells or tissue models (2 sources). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is receptor, target, or pharmacology mechanisms (12 sources), skin, dermatology, antimicrobial, or topical inflammatory outcomes (4 sources), and appetite-related, weight, glucose, or metabolic outcomes (3 sources). Closely related outcome names can still describe different measurements. 5

The CBGA source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

animal study

Cannabigerolic Acid (CBGA) Inhibits the TRPM7 Ion Channel Through its Kinase Domain.

On this page, this source examines THC and receptor, target, or pharmacology mechanisms. 1

Study type
animal study
Population or model
animal models
Outcome focus
receptor, target, or pharmacology mechanisms
Evidence stage
mechanism-focused research

evidence still limited

Development and Validation of a GC-FID Method for the Quantitation of 20 Different Acidic and Neutral Cannabinoids.

On this page, this source examines THC and receptor, target, or pharmacology mechanisms. 2

Outcome focus
receptor, target, or pharmacology mechanisms
Evidence stage
evidence still limited

narrative or expert review

Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review.

On this page, this source examines CBG and safety, adverse-event, impairment, or formulation-specific concerns, CBC and safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns, and CBC and skin and inflammatory dermatology and other related questions. 3

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
safety, adverse-event, impairment, or formulation-specific concerns and safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns and other recorded details
Evidence stage
evidence still limited

narrative or expert review

Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives.

On this page, this source examines CBG and appetite and metabolic outcomes and CBG and anxiety-related outcomes. 4

Study type
narrative or expert review
Outcome focus
appetite-related, weight, glucose, or metabolic outcomes and anxiety-related or neurobehavioral outcomes
Evidence stage
evidence still limited

narrative or expert review

Therapeutic potential of acidic cannabinoids: an update.

On this page, this source examines CBG and pain-related outcomes, CBC and inflammation-related outcomes, and CBDA and nausea-related or inflammation-related outcomes. 5

Study type
narrative or expert review
Population or model
pediatric, adolescent, or developmental context
Outcome focus
pain-related outcomes and inflammation-related or pain-related outcomes and other recorded details
Evidence stage
evidence still limited

Safety and limits

What should readers keep in mind?

Research on CBGA should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 3

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

What is CBGA?

CBGA is a cannabinoid-related compound studied across Receptors and pharmacology, Skin and inflammatory dermatology, Appetite and metabolic outcomes, and Nausea-related or inflammation-related outcomes. This page separates those research questions so they are not mistaken for one broad claim. 7

What has CBGA been studied for?

The current source set includes Receptors and pharmacology, Skin and inflammatory dermatology, Appetite and metabolic outcomes, and Nausea-related or inflammation-related outcomes. Each area may use different doses, products, routes, populations, and outcome measures. 8

How strong is the research on CBGA?

The source set includes human research as well as earlier-stage studies. 9

Is CBGA safe?

Safety cannot be answered for CBGA without context. Dose, route, formulation, medications, and the person using it can all change risk. 10

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Cannabigerolic Acid (CBGA) Inhibits the TRPM7 Ion Channel Through its Kinase Domain. animal study; mechanism-focused research PubMed 38162115 DOI 10.1093/function/zqad069
  2. 2
    Development and Validation of a GC-FID Method for the Quantitation of 20 Different Acidic and Neutral Cannabinoids. evidence still limited PubMed 36257598 DOI 10.1055/a-1962-8165
  3. 3
    Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review. narrative or expert review; evidence still limited PubMed 37630401 DOI 10.3390/molecules28166149
  4. 4
    Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives. narrative or expert review; evidence still limited PubMed 36397993 DOI 10.1155/2022/3336516
  5. 5
    Therapeutic potential of acidic cannabinoids: an update. narrative or expert review; evidence still limited PubMed 41545891 DOI 10.1186/s42238-026-00387-y
  6. 6
    Acidic Cannabinoids Suppress Proinflammatory Cytokine Release by Blocking Store-operated Calcium Entry. narrative or expert review; evidence still limited PubMed 35910331 DOI 10.1093/function/zqac033
  7. 7
    Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. animal study; mechanism-focused research PubMed 21175579 DOI 10.1111/j.1476-5381.2010.01166.x
  8. 8
    Pharmacokinetics of Non-Psychotropic Phytocannabinoids. narrative or expert review; evidence still limited PubMed 40006604 DOI 10.3390/pharmaceutics17020236
  9. 9
    Broad-spectrum bactericidal synergy of silver-cannabichromene-cannabigerol triple combinations against healthcare-associated pathogens. human research PubMed 41983582 DOI 10.1093/jambio/lxag092
  10. 10
    Physiological effect and pharmacokinetic evaluation of combined oral administration of cannabidiolic acid and cannabigerolic acid in dogs. clinical study in people; mechanism-focused research PubMed 41822224 DOI 10.3389/fvets.2026.1779760
  11. 11
    Potency Analysis of Medical Marijuana Products from New York State. human research PubMed 31559335 DOI 10.1089/can.2018.0037
  12. 12
    Single dose and chronic oral administration of cannabigerol and cannabigerolic acid-rich hemp extract in fed and fasted dogs: Physiological effect and pharmacokinetic evaluation. clinical study in people; mechanism-focused research PubMed 35246858 DOI 10.1111/jvp.13048
See all 33 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Acidic Cannabinoids Suppress Proinflammatory Cytokine Release by Blocking Store-operated Calcium Entry. narrative or expert review; evidence still limited / 1 linked research note PubMed 35910331
  2. Therapeutic potential of acidic cannabinoids: an update. narrative or expert review; evidence still limited / 3 linked research notes PubMed 41545891
  3. Quality Control of Traditional Cannabis Tinctures: Pattern, Markers, and Stability. evidence still limited / 1 linked research note PubMed 28117322
  4. Antiviral activities of hemp cannabinoids. cell or laboratory study; mechanism-focused research / 2 linked research notes PubMed 37083031
  5. Raman-Based Differentiation of Hemp, Cannabidiol-Rich Hemp, and Cannabis. evidence still limited / 1 linked research note PubMed 32401504
  6. Physiological effect and pharmacokinetic evaluation of combined oral administration of cannabidiolic acid and cannabigerolic acid in dogs. clinical study in people; mechanism-focused research / 1 linked research note PubMed 41822224
  7. Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review. narrative or expert review; evidence still limited / 4 linked research notes PubMed 37630401
  8. Development and Validation of a GC-FID Method for the Quantitation of 20 Different Acidic and Neutral Cannabinoids. evidence still limited / 1 linked research note PubMed 36257598
  9. Cannabigerolic Acid (CBGA) Inhibits the TRPM7 Ion Channel Through its Kinase Domain. animal study; mechanism-focused research / 1 linked research note PubMed 38162115
  10. Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome. animal study; mechanism-focused research / 1 linked research note PubMed 34980287
  11. Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy. animal study; preclinical research / 1 linked research note PubMed 34384142
  12. Pharmacokinetics of Non-Psychotropic Phytocannabinoids. narrative or expert review; evidence still limited / 2 linked research notes PubMed 40006604
  13. Rapid Antibacterial Activity of Cannabichromenic Acid against Methicillin-Resistant Staphylococcus aureus. cell or laboratory study; evidence still limited / 1 linked research note PubMed 32824356
  14. Enhancing Cannabichromenic Acid Biosynthesis in Saccharomyces cerevisiae. evidence still limited / 1 linked research note PubMed 39808700
  15. In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters. cell or laboratory study; evidence still limited / 1 linked research note PubMed 35306000
  16. Bidimensional heart-cut achiral-chiral liquid chromatography coupled to high-resolution mass spectrometry for the separation of the main chiral phytocannabinoids and enantiomerization studies of cannabichromene and cannabichromenic acid. evidence still limited / 1 linked research note PubMed 37708768
  17. Comparison of decarboxylation rates of acidic cannabinoids between secretory cavity contents and air-dried inflorescence extracts in Cannabis sativa cv. 'Cherry Wine'. evidence still limited / 1 linked research note PubMed 39013926
  18. Direct Quantitation of Phytocannabinoids by One-Dimensional 1H qNMR and Two-Dimensional 1H-1H COSY qNMR in Complex Natural Mixtures. evidence still limited / 1 linked research note PubMed 35566314
  19. Potency Analysis of Medical Marijuana Products from New York State. human research / 1 linked research note PubMed 31559335
  20. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. animal study; mechanism-focused research / 3 linked research notes PubMed 21175579
  21. Single dose and chronic oral administration of cannabigerol and cannabigerolic acid-rich hemp extract in fed and fasted dogs: Physiological effect and pharmacokinetic evaluation. clinical study in people; mechanism-focused research / 1 linked research note PubMed 35246858
  22. The Origin and Biomedical Relevance of Cannabigerol. narrative or expert review; evidence still limited / 1 linked research note PubMed 35887277
  23. Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives. narrative or expert review; evidence still limited / 2 linked research notes PubMed 36397993
  24. Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms. clinical study in people; human research / 2 linked research notes PubMed 34569849
  25. Ensiling conditions and changes of cannabinoid concentration in industrial hemp. preclinical research / 1 linked research note PubMed 39192735
  26. Mapping the research landscape of minor cannabinoids: a bibliometric analysis of research trends and hotspots. mechanism-focused research / 1 linked research note PubMed 41668212
  27. In silico discovery of non-psychoactive scaffolds in Cannabis halting SARS-CoV-2 host entry and replication machinery. mechanism-focused research / 1 linked research note PubMed 35399958
  28. Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 35628241
  29. Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signaling Pathway. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 36769042
  30. Broad-spectrum bactericidal synergy of silver-cannabichromene-cannabigerol triple combinations against healthcare-associated pathogens. human research / 1 linked research note PubMed 41983582
  31. Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. animal study; mechanism-focused research / 3 linked research notes PubMed 21726418
  32. Phytochemical Characterization and TRPA1/TRPM8 Modulation Profile of the Cannabigerol-Rich Cannabis sativa L. Chemotype IV. mechanism-focused research / 2 linked research notes PubMed 38408345
  33. Iodine-mediated cyclization of cannabigerol (CBG) expands the cannabinoid biological and chemical space. mechanism-focused research / 1 linked research note PubMed 30077611